Journal: Journal of Translational Medicine

Article Title: Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis

doi: 10.1186/s12967-025-07529-5

Figure Lengend Snippet: CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue microarray (TMA)-based immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I

Article Snippet: The prostate cancer tissue microarray (TMA) was obtained from Servicebio Technology (#PC-1601).

Techniques: Expressing, Comparison, Immunohistochemical staining, Staining, Marker, Microarray, Immunohistochemistry

Journal: bioRxiv

Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

doi: 10.1101/2025.11.12.687981

Figure Lengend Snippet: ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

Techniques: Immunohistochemistry, Staining

Journal: bioRxiv

Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

doi: 10.1101/2025.11.12.687981

Figure Lengend Snippet: ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

Techniques: Immunohistochemistry, Generated, Microarray, Derivative Assay, Expressing